Current Management Strategies in Oral Submucous Fibrosis

Life Sciences- Oral Medicine

Authors

  • Dr. Simran D. Badki PG, Dept. of Oral Medicine and Radiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research (DMIHER). https://orcid.org/0000-0002-7322-166X
  • Dr. Vidya K. Lohe Professor, Dept. of Oral Medicine & Radiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research (DMIHER)
  • Dr. Rahul Bhowate Professor, Dept. of Oral Medicine & Radiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research (DMIHER)
  • Dr. Suwarna Dangore Professor, Dept. of Oral Medicine & Radiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research (DMIHER)
  • Dr. Mrunal Meshram Assistant Professor, Dept. of Oral Medicine & Radiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research (DMIHER)
  • Dr.Pragati Bhargava PG, Dept. of Oral Medicine & Radiology, Sharad Pawar Dental College & Hospital, Datta Meghe Institute of Higher Education and Research (DMIHER)

DOI:

https://doi.org/10.22376/ijlpr.2023.13.6.L241-L245

Keywords:

OSMF, Atrophica Idiopathica, Fibrous bands, Aloe Vera, spirulina, Pentoxifylline, Chymotrypsin.

Abstract

Oral sub-mucous fibrosis is a premalignant condition recently recognized as "areca nut-induced oral fibrosis." It is "achronic disease which is irreversible, affecting oral and systemic health of patients." However, Areca nut or betel nut is the primaryetiologic reason for Oral Submucous fibrosis (OSMF); other factors like excess chilies intake, nutritional deficiencies, andimmunological factors are also considered causative agents for the disease. It causes inflammation and fibrosis of the submucosaltissues causing trismus and rigid oral mucosa. The treatment for this disorder includes numerous conservative, medicinal, andsurgical management; however, no treatment modality has been proven to be a standard treatment option. Herbal modalities areseen to be more effective in OSMF treatment. Unfortunately, the literature on the management of OSMF cannot do justice to allthe treatment modalities at one stop. The new trends and treatment modalities for OSMF keep adding up from time to time, andyet formulating the perfect treatment protocol for OSMF management is still challenging for dental clinicians due to themultifactorial etiology, complexity of the disease, and changing trends in treatment. The present review aimed to enlighten cliniciansabout the current disease scenario and tried to include all the latest treatment modalities. The objectives are to review and assessthe existing situation of this disease with a brief on the efficacy of different available treatment modalities used to help dentalphysicians formulate a treatment protocol with knowing the proper effects, advantages, and disadvantages of each modality andenlightening the potential future treatment options for OSMF.

References

Pindborg JJ, Sirsat SM. Oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1966;22(6):764-79. doi: 10.1016/0030-4220(66)90367-7, PMID 5224185.

Joshi SG. Fibrosis of the palate and pillars. Indian J Otolaryngol. 1952;4:1-4.

More CB, Rao NR. Proposed clinical definition for oral submucous fibrosis. J Oral Biol Craniofac Res. 2019;9(4):311-4. doi: 10.1016/j.jobcr.2019.06.016, PMID 31334003.

Rao NR, More CB, Brahmbhatt RM, Chen Y, Ming WK. Causal inference and directed acyclic graph: an epidemiological concept much needed for oral submucous fibrosis. J Oral Biol Craniofac Res. 2020;10(4):356-60. doi: 10.1016/j.jobcr.2020.06.008, PMID 32714788.

More CB, Rao NR, More S, Johnson NW. Reasons for initiation of areca nut and related products in patients with oral submucous fibrosis within an endemic area in Gujarat, India. Subst Use Misuse. 2020;55(9):1413-21. doi: 10.1080/10826084.2019.1660678, PMID 32569538.

More C, Peter R, Nishma G, Chen Y, Rao N. Association of Candida species with oral submucous fibrosis and oral leukoplakia: A case-control study. Ann Clin Lab Res. 2018;06(3):248-52. doi: 10.21767/2386-5180.100248.

More C, Shah P, Rao N, Pawar R. Oral submucous fibrosis: an overview with evidence-based management. Int J Oral Health Sci Adv. 2015;3:40-9.

Pindborg JJ, Bhonsle RB, Murti PR, Gupta PC, Daftary DK, Mehta FS. Incidence and early forms of oral submucous fibrosis. Oral Surg Oral Med Oral Pathol. 1980;50(1):40-4. doi: 10.1016/0030-4220(80)90329-1, PMID 6930600.

More CB, Rao NR, Hegde R, Brahmbhatt RM, Shrestha A, Kumar G. Oral submucous fibrosis in children and adolescents: analysis of 36 cases. J Indian Soc Pedod Prev Dent. 2020;38(2):190-9. doi: 10.4103/JISPPD.JISPPD_173_20, PMID 32611867.

More C, Shilu K, Gavli N, Rao NR. Etiopathogenesis and clinical manifestations of oral submucous fibrosis, a potentially malignant disorder: an update. Int J Curr Res. 2018;10:71816-820.

More CB, Gavli N, Chen Y, Rao NR. A novel clinical protocol for therapeutic intervention in oral submucous fibrosis: an evidence-based approach. J Oral Maxillofac Pathol. 2018;22(3):382-91. doi: 10.4103/jomfp.JOMFP_223_18, PMID 30651684.

More C, Pawar R, Rao N, Shah P, Gavli N. Oral ulcer: an overview emphasizing differential diagnosis. Int J Oral Health Sci Adv. 2015;3:1-3.

Koneru A et al. A systematic review of various treatment modalities for oral sub-mucous fibrosis; J of adv Clini & Research; I2014(2):64-72.

Kakar PK, Puri RK, Venkatachalam VP. Oral submucous fibrosis--treatment with hyaline. J Laryngol Otol. 1985;99(1):57-9. doi: 10.1017/s0022215100096286, PMID 3968475.

Kumar K, Srivastava CM, Mathur RM, Pradhan R. The effect of collagenase on oral submucous fibrosis. Indian dent assoc. 1980;52:243-6.

Gupta D, Sharma SC. Oral submucous fibrosis – A new treatment regimen. J Oral Maxillofac Surg. 1988;46(10):830-3. doi: 10.1016/0278-2391(88)90043-2, PMID 3171741.

Haque MF, Meghji S, Nazir R, Harris M. Interferon-gamma (IFN‐gamma) may reverse oral submucous fibrosis. J Oral Pathol Med. 2001;30(1):12-21. doi: 10.1034/j.1600-0714.2001.300103.x, PMID 11140895.

Sudarshan R, Annigeri RG, Sree Vijayabala G. Aloe vera in treating oral submucous fibrosis – a preliminary study. J Oral Pathol Med. 2012;41(10):755-61. doi: 10.1111/j.1600-0714.2012.01168.x. PMID 22650317.

Rai B, Kaur J, Jacobs R, Singh J. Possible action mechanism for curcumin in pre-cancerous lesions based on serum and salivary oxidative stress markers. J Oral Sci. 2010;52(2):251-6. doi: 10.2334/josnusd.52.251, PMID 20587949.

Dr. Fry RR, Dr. Goyal S, Dr. Pandher PK, Dr. Pal Singh Chawla J. An approach to managing OSMF: current status and literature review. Int J Curr Res. 2014;618:10598-604.

Sankaranarayanan Seshadri KS, Elangovan S, VR, Ravi SS. Autologous bone marrow concentrate (mononuclear stem cell) therapy in treating oral submucous fibrosis. J Indian Acad Oral Med Radiol. 2013;25(1):14-8.

Chaudhary Z, Verma M, Tandon S. Treatment of oral submucous fibrosis with ErCr: YSGG laser. Indian J Dent Res. 2011;22(3):472-4. doi: 10.4103/0970-9290.87073, PMID 22048591.

Published

2023-11-01

How to Cite

D. Badki, D. S. ., K. Lohe, D. V. ., Bhowate, D. R. ., Dangore, D. S., Meshram, D. M. ., & Bhargava, D. (2023). Current Management Strategies in Oral Submucous Fibrosis: Life Sciences- Oral Medicine. International Journal of Life Science and Pharma Research, 13(6), L241-L245. https://doi.org/10.22376/ijlpr.2023.13.6.L241-L245

Issue

Section

Review Articles